HLA ligandome tumor antigen discovery for personalized vaccine approach

Hans-Georg Rammensee, Harpreet Singh-Jasuja, Hans-Georg Rammensee, Harpreet Singh-Jasuja

Abstract

Every cancer is different and cancer cells differ from normal cells, in particular, through genetic alterations. HLA molecules on the cell surface enable T lymphocytes to recognize cellular alterations as antigens, including mutations, increase in gene product copy numbers or expression of genes usually not used in the adult organism. The search for cancer-associated antigens shared by many patients with a particular cancer has yielded a number of hits used in clinical vaccination trials with indication of survival benefit. Targeting cancer-specific antigens, which are exclusively expressed on cancer cells and not on normal cells, holds the promise for much better results and perhaps even a cure. Such antigens, however, may specifically appear in very few patients or may be mutated appearing just in one patient. Therefore, to target these in a molecularly defined way, the approach has to be individualized.

Figures

Figure 1.
Figure 1.
A simplified classification of the numerous types of tumor antigens.
Figure 2.
Figure 2.
XPRESIDENT platform, also known as the Tübingen approach, for identification, selection and validation of tumor-associated peptides.

References

    1. Klein G, Sjogren HO, Klein E, Hellstrom KE. . Cancer Res. 1960;20:1561–1572.
    1. Old LJ, Boyse EA. . Harvey Lect. 1973;67:273–315.
    1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. . Nat. Immunol. 2002;3(11):991–998.
    1. Hanahan D, Weinberg RA. . Cell. 2000;100(1):57–70.
    1. Hanahan D, Weinberg RA. . Cell. 2011;144(5):646–674.
    1. Van Rhee F, Kolb HJ. . Curr. Opin. Hematol. 1995;2(6):423–430.
    1. Rodt H, Kolb HJ, Netzel B et al. . Transplant. Proc. 1979;11(1):962–966.
    1. Kantoff PW, Higano CS, Shore ND et al. . N. Engl. J. Med. 2010;363(5):411–422.

    2. This study describes the first FDA approved therapeutic tumor vaccination.

    1. Wolchok JD, Neyns B, Linette G et al. . Lancet Oncol. 2010;11(2):155–164.
    1. Hamid O, Robert C, Daud A et al. . N. Engl. J. Med. 2013;369:134–144.
    1. Wolchok JD, Kluger H, Callahan MK et al. . N. Engl. J. Med. 2013;369(2):122–133.

    2. This report impressively shows the power of the immune system to destroy cancer tissues.

    1. Brentjens RJ, Davila ML, Riviere I et al. . Sci. Transl. Med. 2013;5(177):177ra38.
    1. Grupp SA, Kalos M, Barrett D et al. . N. Engl. J. Med. 2013;368(16):1509–1518.
    1. Powderly JD, Koeppen H, Hodi FS et al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study . J. Clin. Oncol. 2013;31(Suppl., Abstract 3001)
    1. Agrawal N, Jiao Y, Bettegowda C et al. . Cancer Discov. 2012;2(10):899–905.
    1. Kanda M, Matthaei H, Wu J et al. . Gastroenterology. 2012;142(4):730–733. e739.
    1. Hodis E, Watson IR, Kryukov GV et al. . Cell. 2012;150(2):251–263.
    1. Wu J, Jiao Y, Dal Molin M et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways . Proc. Natl Acad. Sci. USA. 2011;108(52):21188–21193.
    1. Parsons DW, Li M, Zhang X et al. . Science. 2011;331(6016):435–439.
    1. Wood LD, Parsons DW, Jones S et al. . Science. 2007;318(5853):1108–1113.
    1. Vogelstein B, Kinzler KW. . Nat. Med. 2004;10(8):789–799.
    1. Kenter GG, Welters MJ, Valentijn AR et al. . N. Engl. J. Med. 2009;361(19):1838–1847.
    1. Scanlan MJ, Simpson AJ, Old LJ. . Cancer Immun. 2004;4:1.
    1. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. . Immunol. Rev. 2002;188:22–32.
    1. Kantoff PW, Schuetz TJ, Blumenstein BA et al. . J. Clin. Oncol. 2010;28(7):1099–1105.
    1. Hirayama M, Nishikawa H, Nagata Y et al. . Eur. J. Immunol. 2013;43(4):989–1000.
    1. Rittig SM, Haentschel M, Weimer KJ et al. . Mol. Ther. 2011;19(5):990–999.
    1. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. . Nature. 1991;351(6324):290–296.
    1. Walter S, Weinschenk T, Stenzl A et al. . Nat. Med. 2012

    2. This study shows immune responses against vaccine peptides to be associated with clinical benefit and is the first controlled study in humans showing the effect of low-dose cyclophosphamide on regulatory T cells.

    1. Feyerabend S, Stevanovic S, Gouttefangeas C et al. . Prostate. 2009;69(9):917–927.
    1. Oosterwijk E, Boerman OC, Oyen WJ, Old LJ, Mulders PF. . World J. Urol. 2008;26(2):141–146.
    1. Howland SW, Tsuji T, Gnjatic S, Ritter G, Old LJ, Wittrup KD. . J. Immunother. 2008;31(7):607–619.
    1. Weinschenk T, Gouttefangeas C, Schirle M et al. . Cancer Res. 2002;62(20):5818–5827.
    1. Singh-Jasuja H, Emmerich NP, Rammensee HG. . Cancer Immunol. Immunother. 2004;53(3):187–195.
    1. Rammensee HG, Weinschenk T, Gouttefangeas C, Stevanovic S. . Immunol. Rev. 2002;188:164–176.
    1. Wang RF, Rosenberg SA. . Immunol. Rev. 1999;170:85–100.
    1. Rammensee HG, Falk K, Rotzschke O. . Annu. Rev. Immunol. 1993;11:213–244.
    1. Kowalewski DJ, Stevanovic S. . Methods Mol. Biol. 2013;960:145–157.
    1. Hillen N, Stevanovic S. . Expert Rev. Proteomics. 2006;3(6):653–664.
    1. Stevanovic S, Schild H. . Semin. Immunol. 1999;11(6):375–384.
    1. Nishikawa H, Kato T, Tawara I et al. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts . Proc. Natl Acad. Sci. USA. 2005;102(26):9253–9257.
    1. Dutoit V, Herold-Mende C, Hilf N et al. . Brain. 2012;135:1042–1054. Pt 4.
    1. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. . Immunogenetics. 1999;50(3)(4):213–219.
    1. Castle JC, Kreiter S, Diekmann J et al. . Cancer Res. 2012;72(5):1081–1091.
    1. Lu YC, Yao X, Li YF et al. . J. Immunol. 2013;190(12):6034–6042.
    1. Weinzierl AO, Lemmel C, Schoor O et al. . Mol. Cell Proteomics. 2007;6(1):102–113.
    1. Matsushita H, Vesely MD, Koboldt DC et al. . Nature. 2012;482(7385):400–404.
    1. Schreiber RD, Old LJ, Smyth MJ. . Science. 2011;331(6024):1565–1570.
    1. Fridman WH, Dieu-Nosjean MC, Pages F et al. . Cancer Microenviron. 2012;6(2):117–122.

    2. This study illustrates the power of the patients' immune response to fight their cancer.

    1. Galon J, Franck P, Marincola FM et al. . J Transl. Med. 2012;10(1):205.

    2. This study uses quality analysis of immune responses within the tumor for prognosis.

    1. Charoentong P, Angelova M, Efremova M et al. . Cancer Immunol. Immunother. 2012;61(11):1885–1903.
    1. Rammensee HG. . Immunol. Cell Biol. 2006;84(3):290–294.
Websites
    1. SYFPEITHI - a database of MHC ligands and peptide motifs (Ver. 1.0)
    1. CIMT.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit